SCHEDULE: DAYLI Filers Divest Trinity Biotech Stake
Beneficial Ownership Update
DAYLI Filers report complete divestment of their beneficial ownership in Trinity Biotech plc following the 2025 MiCo IVD Purchase by AI n M.
Summary
- DAYLI Filers, comprising DAYLI Partners, Inc., DAYLI TRINITY HOLDINGS, Ltd., and DAYLI Fountainhead Project No.3 Private Equity Fund, have filed Amendment No. 7 to their Schedule 13D.
- The amendment reports a change in their beneficial ownership of Trinity Biotech plc Class 'A' Ordinary Shares.
- On December 2, 2025, DAYLI Holdings and AI n M completed the 2025 MiCo IVD Purchase.
- As a result of this transaction, the DAYLI Filers no longer hold any equity interest in MiCo IVD and, consequently, have no direct or indirect equity interest in Trinity Biotech plc.
- The aggregate beneficial ownership of the DAYLI Filers in Trinity Biotech plc is now 0.0%.
- The Joint Filing Agreement by the DAYLI Filers, initially filed on December 19, 2024, has been revoked.
Sentiment
Score: 5
Explanation: Neutral. The filing reports a factual change in beneficial ownership by an investment group, which has fully divested its stake. This does not inherently reflect positively or negatively on the issuer's current operations or future prospects, though a major investor exit could be interpreted differently by the market.
Future Outlook
No forward-looking statements or guidance regarding Trinity Biotech plc's operations or financial performance are provided in this filing, as it pertains solely to a change in beneficial ownership by an investment group.
Industry Context
This filing primarily concerns a change in beneficial ownership by an investment group and does not provide sufficient information to analyze broader industry trends or competitive positioning for Trinity Biotech plc.
Stakeholder Impact
- Shareholders: The complete divestment by a previously significant investor group (DAYLI Filers) could lead to market speculation or a slight shift in investor sentiment, depending on how the market interprets the exit.
Key Dates
| Date | Description |
|---|---|
| 2022-12-07 | Original Schedule 13D filed by MiCo Co., Ltd. and MiCo IVD Holdings, LLC. |
| 2024-01-02 | Amendment No. 1 filed by MiCo Parent reporting sale of MiCo IVD equity interests to Mainstream Holdings. Also, Amendment No. 2 to Schedule 13D filed by MiCo IVD, Mainstream Holdings, Mainstream New Growth No. 1 Private Equity Fund, New Main Equity Co., Ltd. and Kim Chang-hee. |
| 2024-12-19 | Amendment No. 3 to Schedule 13D filed by MiCo IVD, DAYLI TRINITY HOLDINGS, DAYLI Fountainhead, and DAYLI Partners, with DAYLI Filers joining as reporting persons and initial Joint Filing Agreement. |
| 2024-12-20 | Amendment No. 4 to Schedule 13D filed by New Main Equity Filers reporting sale by Mainstream Holdings of MiCo IVD equity interests to DAYLI Holdings. |
| 2025-12-02 | Date of event requiring this filing; DAYLI Holdings and AI n M completed the 2025 MiCo IVD Purchase, leading to DAYLI Filers ceasing beneficial ownership in Trinity Biotech plc. |
| 2025-12-04 | Amendment No. 5 to Schedule 13D filed by MiCo IVD, AI n M and Wonyong Park. |
| 2025-12-10 | Amendment No. 6 to Schedule 13D filed by MiCo IVD, AI n M and Joon Ho Lee. |
| 2025-12-15 | Date of signing of this Amendment No. 7 by DAYLI Filers. |
Recommendation
holdThe filing details the complete divestment of beneficial ownership in Trinity Biotech plc by the DAYLI Filers. This is a transactional report and does not provide insights into the operational performance, financial health, or strategic outlook of Trinity Biotech plc. Without additional fundamental information about the company, a 'hold' recommendation is appropriate as this specific filing does not present a clear catalyst for a 'buy' or 'sell' decision, though the exit of a significant investor could introduce some market uncertainty.
Keywords
Trinity Biotech plc, Class A Ordinary Shares, Schedule 13D/A, Beneficial Ownership, Divestment, DAYLI Partners, DAYLI TRINITY HOLDINGS, DAYLI Fountainhead, MiCo IVD Purchase, AI n M, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.